close
close
From Foods, Astrazeneca, Amazon, Deutsche Bank and Porsche

From Foods, Astrazeneca, Amazon, Deutsche Bank and Porsche

by

Associated British Foods, the owner of Primark, reported the profit and sales of input tax for the first half below expectations due to challenges in the sugar business.

The FTSE 100 (^ftse) conglomerate announced on Tuesday that the input tax for the 24 weeks until March 1 to 692 million GBP decreased, which was decreasing by 21% compared to the same period of the previous year. The number was far below the forecasts of the analysts of 828 million GBP.

The group's sugar business recorded an operational loss of 16 million GBP, which was towed by persistently low European sugar prices and underperformance in its bioethanolarm Vivergo based in Great Britain.

The managing director George Weston was disappointed with the performance of the division.

“These results reflect a robust performance in four of our five departments,” he said.

“I am frustrated with the results of our sugar business, but we are clear what needs to be done by operational and regulatory solutions to improve financial performance.

Read more: The HSBC winnings are less than expected because the bank announces a purchase of up to USD 3 billion

“Primark has achieved good growth in Europe and the USA. In the UK, consumer warning in Great Britain. Primarks profit and margin delivery was strong and our cost-effective operating model works well.”

The company expects that it will continue to hold a challenge for Primark in Great Britain in the second half of 2025, although the latest trends indicate a certain stabilization.

Astrazeneca's shares rose by 4%in the trade in London, as investors more than expected and overlooked a robust performance in oncology and instead concentrated on the sales giant of the pharmaceutical giant in the first quarter.

The Anglo-Swedish pharmaceutical maker made a total turnover of $ 13.59 billion for the three months until March 31, which the analysts did not go back. However, the core profit per share of certain costs and one-time items excluded by 21% to $ 2.49, which conveniently defeated expectations. The registered result per share rose by 34% to USD 1.88.

Despite the mixed results, the company confirmed its instructions for the year as a whole and claimed expectations for a one -story percentage growth of total sales and a percentage percentage of the core profit per share with a low percentage increase in the exchange rates.

The growth was recorded in all important geographical markets, although the analysts described the performance in China as “soft”, which dampened the wider results.

Oncology remained the most important growth engine for astrazeneca, whereby the group has been highlighting five positive phase -iii test report since the previous quarter update.

Leave a Comment